Drugs / peppermint
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05251337 | Mar 2022 → Jun 2023 | anxiety, chemotherapy-induced toxicity | Indiana University | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT07103460 | Jul 2025 → Jul 2027 expected | pneumonia, type 2 diabetes mellitus | National Taipei University of Nursing and Health Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peppermint | “three commonly used essential oils (wintergreen, peppermint, and eucalyptus) will be integrated into IS respiratory training” NCT07103460 ↗ |